Diabetes Mellitus, Type 2 Diabetes Mellitus, Type 2
Conditions
Interventions
Sponsors
Maruyama Shoichi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -patients with stable type 2 diabetes -eGFR(Crteatinine)<= 60mL/min/1.73m2 -patients who are taking renin angiotensin system inhibitors (exclude intolerable or non-adaptive) -older than 18 years -written consent
Exclusion criteria
Exclusion criteria: -SGLT2 inhibitors users within 8 weeks -30<eGFR(Crteatinine) mL/min/1.73m2 -under maintenance dialysis therapy or history of kidney plantation -diuretics users -patients who are taking both ACEi and ARB (renin inhibitor) -active nephritis or kidney disease -obvious steroid diabetes -patients whose ALT and AST levels exceed 2.0 times the facility standard value -heart failure NYHA class 4 -pregnant, or desiring to bear children -inapporopriate for this study as judged by attending investigateor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of change in FF (filtration fraction) after 4 weeks of treatment relative to the baseline between canagliflozin intervention group and control group | — |
Secondary
| Measure | Time frame |
|---|---|
| -Change in FF after 4 weeks of treatment relative to the baseline between canagliflozin intervention group and control group -Rate of change and change in Cin (glomerular filtration rate by inulin) after 4 weeks of treatment relative to the baseline between canagliflozin intervention group and control group -Rate of change and change in RPR (renal plasma flow) after 4 weeks of treatment relative to the baseline between canagliflozin intervention group and control group -Rate of change and change in RBR (renal blood flow) after 4 weeks of treatment relative to the baseline between canagliflozin intervention group and control group -Rate of change and change in RVR (renal vascular resistance) after 4 weeks of treatment relative to the baseline between canagliflozin intervention group and control group -Change in eGFR, HbA1c and albuminuria (proteinuria) after 4 and 12 weeks of treatment relative to the baseline between canagliflozin intervention group and control group -Change in blood pressure and body weight after 4 and 12 weeks of treatment relative to the baseline between canagliflozin intervention group and control group -Change in urinary angiotensinogen after 4 and 12 weeks of treatment relative to the baseline between canagliflozin intervention group and control group -Change in urinary MCP-1, NAG, beta2MG, L-FABP after 4 and 12 weeks of treatment relative to the baseline between canagliflozin intervention group and control group -Change in serum erythropoietin and hematocrit after 4 and 12 weeks of treatment relative to the baseline between canagliflozin intervention group and control group -Change in serum vasopressin (instead of copeptin), renin, aldosterone, and sodium after 4 and 12 weeks of treatment relative to the baseline between canagliflozin intervention group and control group | — |
Contacts
Public ContactSawako Kato
Nagoya University Graduate School of Medicine
Outcome results
None listed